Seeking Alpha

Mixed news for diabetes drugs

  • AstraZeneca's (AZN) and Bristol-Myers Squibb's (BMY) approved Type 2 diabetes treatment Onglyza was unexpectedly linked with a small rise in hospitalizations for heart failure - where the heart is unable to pump blood properly - in a large-scale two-year study. The problem affected 3.5% of patients vs 2.8% in a control group.
  • However, Onglyza didn't increase the risk of "cardiovascular death, heart attack or stroke."
  • The drug, along with Takeda's Nesina, wasn't associated with higher rates of inflammation of the pancreas or cancer, which had previously been a concern.
  • Onglyza and Nesina work by inhibiting dipeptidyl peptidase-4, or DPP-4, in order to strengthen the body's ability to reduce high blood-sugar levels. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs